Knight Therapeutics Inc. announced that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Knight has previously submitted marketing authorization applications for fostamatinib in Colombia and Mexico. On May 24, 2022, Knight announced that it entered into an agreement with Rigel Pharmaceuticals Inc. for the exclusive rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.

Fostamatinib is commercially available in the United States under the brand name TAVALISSE and in Europe under the brand name TAVLESSE for the treatment of adult chronic ITP.